DEFA14A: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Published on April 18, 2025
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
––––––––––––––––––––––––––––––––––
SCHEDULE 14A
––––––––––––––––––––––––––––––––––
Proxy Statement Pursuant to Section 14(a) (Rule 14a-101) of the
Securities Exchange Act of 1934
|
Filed by the Registrant |
☒ |
|
|
Filed by a Party other than the Registrant |
☐ |
Check the appropriate box:
|
☐ |
Preliminary Proxy Statement |
|
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive Proxy Statement |
|
|
☒ |
Definitive Additional Materials |
|
|
☐ |
Soliciting Material Pursuant to §240.14a-12 |
Envoy Medical, Inc.
(Name of Registrant as Specified in its Charter)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
☒ |
No fee required. |
|
|
☐ |
Fee paid previously with preliminary materials. |
|
|
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
CONTROL ID: REQUEST ID: |
|||||
|
ENVOY MEDICAL, INC |
|||||
|
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS |
|||||
|
DATE: |
Wednesday, May 28, 2025 |
||||
|
TIME: |
3:00 PM Central Time |
||||
|
LOCATION: |
Fairfield Inn & Suites, 1125 Co Rd E East, Vadnais Heights, |
||||
|
HOW TO REQUEST PAPER COPIES OF OUR MATERIALS |
|||||
|
PHONE: |
FAX: |
INTERNET: |
EMAIL: |
||
|
This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/COCH |
|||||
|
If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before May 14, 2025. |
|||||
|
you may enter your voting instructions at https://www.iproxydirect.com/COCH |
|||||
|
The purposes of this meeting are as follows: |
|||||
|
1. To elect two Class II director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve until the earlier of the 2028 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal; 2. To ratify the appointment of Grant Thornton LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2025; 3. To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation; 4. To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan; and 5. to transact such other business as may properly come before the annual meeting or any adjustment thereof. |
|||||
Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.
The board of directors has fixed the close of business on April 10, 2025 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our Class A common stock, par value $0.0001 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.
The Board of Directors recommends that you vote ‘for’ all proposals above.
Please note — This is not a Proxy Card — you cannot vote by returning this card
|
ENVOY MEDICAL, INC |
FIRST-CLASS MAIL |
|||
|
Time Sensitive shareholder information enclosed |
||||
|
IMPORTANT SHAREHOLDER INFORMATION |
||||
|
your vote is imporant |
||||
|
ENVOY MEDICAL, INC |
FIRST-CLASS MAIL |
|||
Time Sensitive shareholder information enclosed
IMPORTANT SHAREHOLDER
INFORMATION
your vote is imporant